NasdaqGM:NRIXBiotechs
How Investors May Respond To Nurix Therapeutics (NRIX) Deepening Losses And Sharply Lower Collaboration Revenue
Nurix Therapeutics, Inc. reported past second-quarter and six-month results to May 31, 2026, with revenue falling to US$9.04 million for the quarter and a net loss of US$89.54 million, and six-month revenue of US$15.30 million alongside a net loss of US$176.71 million.
The widening basic loss per share from continuing operations, rising to US$0.81 for the quarter and US$1.60 for the half year, highlights growing cost pressures relative to sharply lower collaboration and operating...